200 related articles for article (PubMed ID: 35832083)
1. Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives.
Roemhild K; Besse HC; Wang B; Peña Q; Sun Q; Omata D; Ozbakir B; Bos C; Scheeren HW; Storm G; Metselaar JM; Yu H; Knüchel-Clarke R; Kiessling F; Moonen CTW; Deckers R; Shi Y; Lammers T
Theranostics; 2022; 12(10):4791-4801. PubMed ID: 35832083
[No Abstract] [Full Text] [Related]
2. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.
Haisma HJ; van Muijen M; Pinedo HM; Boven E
Cell Biophys; 1994; 24-25():185-92. PubMed ID: 7736523
[TBL] [Abstract][Full Text] [Related]
5. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
6. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
7. A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase.
Besse HC; Chen Y; Scheeren HW; Metselaar JM; Lammers T; Moonen CTW; Hennink WE; Deckers R
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32532061
[TBL] [Abstract][Full Text] [Related]
8. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
9. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.
Tranoy-Opalinski I; Legigan T; Barat R; Clarhaut J; Thomas M; Renoux B; Papot S
Eur J Med Chem; 2014 Mar; 74():302-13. PubMed ID: 24480360
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
11. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
12. A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Compain G; Oumata N; Clarhaut J; Péraudeau E; Renoux B; Galons H; Papot S
Eur J Med Chem; 2018 Oct; 158():1-6. PubMed ID: 30199702
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of the prodrug of class I major histocompatibility peptide GILGFVFTL activated by beta-glucuronidase.
Rawale S; Hrihorczuk LM; Wei WZ; Zemlicka J
J Med Chem; 2002 Feb; 45(4):937-43. PubMed ID: 11831906
[TBL] [Abstract][Full Text] [Related]
14. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug.
Miller SD; Mohiuddin I; Cao XX; Ozvaran MK; Daniel JC; Roy Smythe W
J Surg Res; 2004 Oct; 121(2):153-8. PubMed ID: 15501454
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
18. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
19. Beta-glucuronidase-mediated drug release.
de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
[TBL] [Abstract][Full Text] [Related]
20. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
